AA
CRVS icon

ALPS Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

ALPS Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$998K Buy
68,194
+6,876
+11% +$110K ﹤0.01% 586
2025
Q4 		$472K Buy
+61,318
New +$484K ﹤0.01% 775

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ALPS Advisors's CRVS Position: Q1 2026 in Review

ALPS Advisors increased its Corvus Pharmaceuticals (CRVS) stake by 11% in Q1 2026, buying an estimated $110K and bringing the position to 68,194 shares worth $998K. The position accounts for ﹤0.01% of the portfolio, ranked #586.

ALPS Advisors first reported a position in CRVS in Q4 2025 and has held it in 2 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • ALPS Advisors held 68,194 shares of Corvus Pharmaceuticals worth $998K as of Q1 2026.
  • ALPS Advisors bought 6,876 Corvus Pharmaceuticals shares in Q1 2026, an estimated $110K.
  • Corvus Pharmaceuticals made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #586 holding.
  • ALPS Advisors first reported a position in Corvus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.